ESR1 and breast carcinoma: While ENDX is equipotent with 4-HT26, 4-HT was not included as a comparator in this study, as clinically attainable serum concentrations of 4-HT reported in ERα+ breast cancer patients receiving 20 mg/day TAM monotherapy is <5 nM27,28.